type 2 diabetis. Non-insulin dependent diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group:168 coenzyme q10 capsules(100 mg) will be given to patients and ask them to use 2 of them with their lunch and dinner. Intervention 2: control group:168 coenzyme pla
Treatment - Drugs
Intervention group:168 coenzyme q10 capsules(100 mg) will be given to patients and ask them to use 2 of them with their lunch and dinner.
control group:168 coenzyme placebo capsules will be given to patients and ask them to use 2 of them with their lunch and dinner.
Sponsors
Research center Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 58 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: men and women aged between 20 to 60 years old, Body mass index(BMI) between 25 to35; diabetes mellitus disease duration for 2-15 years; having a stable diet and exercise plan and havinga fix drug schedule. Exclusion criteria: history of clinical signs or symptoms of GI diseases, liver disease, renal disease, coronary artery disease, thyroid diseases, respiratory disease, hypertension, type 1 diabetes and cancer; history of using drugs, such as anti- hypertensive, anti hyperlipidemia, diuretic, esterogene, progesterone, OCP, vitamin or omega 3 supplement, insulin injection and alcohol abuse; cigarette smoking; pregnancy and lactation.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma ADMA. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: Elisa kit.;Fasting Blood Glucose. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: Enzymatic calorimetric.;HbA1c. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: HPLC.;Serum Fasting Insulin. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: Radioimmuno assey.;Insulin sensitivity index. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: Calculation.;Insulin resistance index. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: Calculation.;Serum nitric oxide. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: Measurment.;Serum Triglyceride. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: Enzymatic calorimetric.;Serum Total Cholestrol. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: Enzymatic calorimetric.;HDL-cholesterol. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: Enzymatic calorimetric.;LDL-cholesterol. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: Turbidometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: seca scale.;Height. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: meter.;Waist circumference. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: meter.;Hip circumference. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: meter.;Waist/Hip ratio. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: calculation.;BMI. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: calculation.;SBP AND DBP. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: manometer.;Macronutrients. Timepoint: At the beginning and at the end of 12 weeks. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRoya Kolahdouz Mohammadi
Faculty of Public health,Tehran University of Medical Sciences
Outcome results
None listed